Similar articles for PMID: 19048115

Year	Number of Results
1994	2
1995	1
1998	3
1999	3
2000	2
2001	2
2002	3
2003	3
2004	1
2005	4
2006	6
2007	2
2008	7
2009	4
2010	4
2011	2
2012	3
2013	6
2014	5
2015	8
2016	10
2017	7
2018	4
2019	7
2020	4
2021	3
2022	6
2023	1
2024	0

1

Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, Cho KR. Sangha N, et al. Neoplasia. 2008 Dec;10(12):1362-72, following 1372. doi: 10.1593/neo.08784. Neoplasia. 2008. PMID: 19048115 Free PMC article.

2

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A. Rechsteiner M, et al. Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18. Exp Mol Pathol. 2013. PMID: 23965232

3

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.

Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA. Redig AJ, et al. Clin Cancer Res. 2016 Jul 1;22(13):3148-56. doi: 10.1158/1078-0432.CCR-15-2377. Epub 2016 Feb 9. Clin Cancer Res. 2016. PMID: 26861459 Free PMC article.

4

Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.

Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice JM, Nomura T. Fujita M, et al. Jpn J Cancer Res. 1994 Dec;85(12):1247-56. doi: 10.1111/j.1349-7006.1994.tb02937.x. Jpn J Cancer Res. 1994. PMID: 7852189 Free PMC article.

5

Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.

McCool KW, Freeman ZT, Zhai Y, Wu R, Hu K, Liu CJ, Tomlins SA, Fearon ER, Magnuson B, Kuick R, Cho KR. McCool KW, et al. Cancer Res. 2020 Feb 15;80(4):877-889. doi: 10.1158/0008-5472.CAN-19-2558. Epub 2019 Dec 5. Cancer Res. 2020. PMID: 31806642 Free PMC article.

6

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS. Mackenzie R, et al. BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8. BMC Cancer. 2015. PMID: 25986173 Free PMC article.

7

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IeM, Wang TL. Kuo KT, et al. Cancer Res. 2009 May 1;69(9):4036-42. doi: 10.1158/0008-5472.CAN-08-3913. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383911 Free PMC article.

8

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

Hayashi T, Desmeules P, Smith RS, Drilon A, Somwar R, Ladanyi M. Hayashi T, et al. Clin Cancer Res. 2018 Mar 15;24(6):1436-1447. doi: 10.1158/1078-0432.CCR-17-2343. Epub 2017 Nov 10. Clin Cancer Res. 2018. PMID: 29127119 Free PMC article.

9

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS). Emmanuel C, et al. Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316818

10

Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN. Birch AH, et al. PLoS One. 2011;6(12):e28250. doi: 10.1371/journal.pone.0028250. Epub 2011 Dec 6. PLoS One. 2011. PMID: 22163003 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year